It has long been thought that Cymbalta (generic name duloxetine) would be the second medication to receive FDA approval for the treatment of fibromyalgia. However, the disappointing results of the third phase III efficacy study could stall Lilly’s quest for approval. The 27-week phase III clinical trial randomized 330 fibromyalgia patients to either a 60 mg or 120 mg per day dose or to a placebo. Patients were allowed to switch between the 60 and 120 mg dosages during the study according...


10 Things Not to Say to Someone With Depression
6 Behavior Changes During Depression
Getting to Know Your 5 Essential Brain Chemicals
10 Surprising Ways to Enhance Your Mind